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Abstract
Background: The limited efficacy of current treatments against pancreatic cancer has prompted the search of new
alternatives such as virotherapy. Activation of the immune response against cancer cells is emerging as one of the
main mechanisms of action of oncolytic viruses (OV). Direct oncolysis releases tumor antigens, and viral replication
within the tumor microenvironment is a potent danger signal. Arming OV with immunostimulatory transgenes
further enhances their therapeutic effect. However, standard virotherapy protocols do not take full advantage of OV
as cancer vaccines because repeated viral administrations may polarize immune responses against strong viral
antigens, and the rapid onset of neutralizing antibodies limits the efficacy of redosing. An alternative paradigm
based on sequential combination of antigenically distinct OV has been recently proposed.
Methods: We have developed a protocol consisting of sequential intratumor administrations of new Adenovirus
(Ad) and Newcastle Disease Virus (NDV)-based OV encoding the immunostimulatory cytokine oncostatin M (OSM).
Transgene expression, toxicity and antitumor effect were evaluated using an aggressive orthotopic pancreatic
cancer model in Syrian hamsters, which are sensitive to OSM and permissive for replication of both OVs.
Results: NDV-OSM was more cytolytic, whereas Ad-OSM caused higher OSM expression in vivo. Both viruses
achieved only a marginal antitumor effect in monotherapy. In addition, strong secretion of OSM in serum limited
the maximal tolerated dose of Ad-OSM. In contrast, moderate doses of Ad-OSM followed one week later by
NDV-OSM were safe, showed a significant antitumor effect and stimulated immune responses against cancer cells.
Similar efficacy was observed when the order of virus administrations was reversed.
Conclusion: Sequential administration of oncolytic Ad and NDV encoding OSM is a promising approach against
pancreatic cancer.
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Background
Pancreatic cancer is one of the most aggressive human
solid tumors. Typical characteristics include rapid
growth, infiltration and early metastatic spread. Surgical
resection with negative margins continues to be the only
potential cure, but only 10–20 % of patients with pan-
creatic ductal adenocarcinoma (PDAC) have primarily
resectable disease at first diagnosis. Forty percent will
have metastatic disease, and another 30–40 % will have
locally advanced neoplasms. This results in a median
overall survival in patients with primarily resectable tu-
mors of 20–24 months, and 9–13 months in locally ad-
vanced tumors, with a 95 % mortality rate five years
after diagnosis [1, 2]. Thus, there is an urgent need to
identify effective therapies for pancreatic cancer.
Oncolytic viruses (OV) adapted as gene therapy vec-
tors for the expression of immunostimulatory cytokines
are emerging as a promising approach for the treatment
of solid tumors [3]. To date, the most prominent and
clinically advanced representatives of this new class of
agents are the herpes simplex virus type 1-derived T-
VEC and the vaccinia virus-derived Pexa-Vec viruses,
both expressing granulocyte-macrophage colony-
stimulating factor (GM-CSF) as a therapeutic gene [4].
Recent trials provide proof of concept for clinical effi-
cacy in advanced melanoma (T-VEC) [4, 5] and hepato-
carcinoma (Pexa-Vec) [6], beyond that observed with
previous versions of these OVs lacking therapeutic
genes. The proposed mechanism of action includes the
combination of viral effects (direct oncolysis, release of
tumor antigens, danger signals and inflammation) and
the additional stimulation of the immune system medi-
ated by the cytokine expressed from the virus. Since tol-
erance to these agents has been generally good,
intensification of treatments using higher doses or more
potent cytokines would be the next logical step to in-
crease response rates. However, antiviral neutralizing
antibodies induced after the first virus dose may inhibit
the infectivity of subsequent vector administrations. Fur-
thermore, repeated vector doses may stimulate cellular
immune responses against the virus that might outcom-
pete antitumor responses. It should also be considered
that increasing viral doses to compensate for a reduction
in the number of administrations is not always possible,
particularly when high transgene levels cause toxicity.
An alternative to these protocols is the sequential
administration of antigenically distinct viruses. The
principle of prime and boost is employed for vaccination
against different pathogens [7], and it has been recently
proposed in the field of OV with the objective of in-
creasing the immune responses against tumor antigens.
Tysome et al. demonstrated that sequential intratumoral
administration of wild type adenovirus (Ad) followed by
vaccinia virus has a greater therapeutic effect than
repeated doses of the same virus, and that stimulation of
cellular immune responses against cancer cells plays an
important role [8]. We hypothesize that this concept can
be applied to other OV combinations and that the in-
corporation of potent immunostimulatory cytokines as
therapeutic genes in these viruses can further enhance
their antitumor effect. The use of different armed viruses
without cross humoral responses would allow at least
two short cycles of transgene expression. The duration
of each cycle will be intrinsically limited by the tumor
cells, the viral replication cycle and the cytolytic nature
of the viruses. Therefore, we consider that cytokines that
promote antigen presentation and co-stimulatory signals
such as oncostatin M (OSM) are highly suited to arm
OV aimed at triggering antitumor immunity. OSM be-
longs to the interleukin (IL)-6 family, together with IL-6,
cardiotrophin-1, IL-11, leukemia inhibitory factor (LIF),
and ciliary neurotrophic factor [9]. OSM binds at least
two heterodimeric transmembrane receptors on the sur-
face of cells, one composed of the specific OSM receptor
subunit (OSMR) plus the gp130 moiety, and another
comprising gp130 plus the LIF receptor (LIFR) subunit
[10]. The receptors are expressed in connective tissues,
neurons and a variety of epithelial cells. Downstream
signaling involves Janus tyrosine kinases (Jak1, Jak2 and
Tyk2) as well as STAT1 and STAT3 transcription factors
[11]. OSM exerts different biological effects depending
on the pattern and localization of expression. It can be
secreted by monocytes, macrophages, dendritic cells and
neutrophils as a mediator of acute inflammatory re-
sponses, similar to IL-6 [12–16]. In addition, OSM act-
ing on hepatocytes plays a role in the adaptive response
against viral hepatitis by stimulating the expression of
genes involved in activation and expansion of lympho-
cytes (such as IL-15Rα and ICAM1) [17, 18]. When
OSM acts in the presence of type I interferon (IFN), it
can also activate the machinery of antigen processing
and presentation in epithelial cells by increasing the
expression of HLA, β2-microglobulin, Tap1, Tap2 and
proteasome subunits, among others [17]. Short-term
treatment of hepatocellular carcinoma with recombin-
ant OSM promoted cell differentiation and increased
susceptibility to chemotherapy in vitro and in vivo
[19]. Similarly, transient expression of OSM using gene
therapy vectors has shown antitumoral effect in melan-
oma models, in part through inhibition of cell prolifer-
ation and induction of apoptosis [20]. In contrast,
chronic OSM production has been associated with pro-
gression of other tumors such as breast cancer, through
stimulation of angiogenesis, epithelial-mesenchymal
transition and invasiveness [21]. Therefore, the func-
tional profile of OSM is compatible with its use as a
therapeutic gene in the context of transient expression
by OVs.
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In the present study, we produced oncolytic Ad and
Newcastle disease virus (NDV) carrying this transgene.
Ad is a double-stranded DNA virus with naked capsids
of approximately 100 nm in diameter. It presents moder-
ate oncolytic potency and is very efficient in priming im-
mune responses [22]. In addition Ad has a very stable
non-integrating genome and efficient recombinant gene
expression machinery. Ad can be routinely produced to
high titers for clinical use and research has long con-
firmed the safety of these agents as OV in patients [23].
NDV is a single negative stranded RNA paramyxovirus
with membrane-enveloped particles of 150–350 nm in
diameter [24]. Its lytic cycle is faster than Ad (24 h ver-
sus 48 h, on average), and it favors a pro-inflammatory
microenvironment in tumors, through stimulation of
type I IFN and chemokine production [25], as well as
activation of macrophages [26] and natural killer cells
[27], which modify the local tumor microenvironment
and generate a potent local antitumor response. Few
individuals present neutralizing NDV antibodies and it
is one of the safest OV for humans since it is a bird
adapted virus with little chances of adapting to the
human host. Furthermore, it has tumor selective rep-
lication properties [24, 28].
In the present study, we used an orthotopic pancreatic
cancer model established in Syrian hamsters to evaluate
the toxicity and antitumor effect of Ad and NDV ex-
pressing human OSM (hOSM), alone or in different
combinations. Although tools to study hamster immune
response are limited, this animal model offers important
features for the study of virotherapy because it is im-
mune competent, permissive for Ad and NDV, and sen-
sitive to a variety of human cytokines such as OSM and
IL-12 [29, 30]. In addition, hamster pancreatic cancer
cell lines such as HaP-T1 recapitulate important genetic
abnormalities found in human PDAC, such as the acti-
vating G12D mutation in the K-ras oncogene [31]. These
characteristics, together with the aggressiveness con-
ferred by the anatomical localization of tumors, make
this model a stringent test for the safety and efficacy of
armed OVs. Herein we describe the properties and limi-
tations of each virus and highlight the importance of
combination protocols to obtain the optimal therapeutic
effect.
Results
Oncolytic Ad and NDV replicate and destroy pancreatic
cancer cells from humans and Syrian hamsters
The armed OVs, OAV-H-OSM and NDV-LaSota-F3aa-
OSM were obtained by incorporating the hOSM cDNA
sequence into the genome of oncolytic Ad and NDV vi-
ruses, respectively. Ad were derived from human sero-
type 5. These agents are called hereinafter Ad-OSM and
NDV-OSM. In the Ad-OSM virus the transgene was
placed in the E3 region, as depicted in Fig. 1a. Condi-
tional replication of this virus was achieved by eliminat-
ing the pRB-binding domain of E1A, plus transcriptional
control of E1A using a hypoxia-responsive promoter, as
previously described [29, 32]. NDV-OSM carries OSM
inserted between the P and M genes, and a modified
fusogenic protein (F) cleavage site designed to increase
its lytic and immunostimulatory properties [33] (Fig. 1a).
PDAC cell lines from humans (PANC-1) and Syrian
hamsters (HaP-T1) were infected with these viruses, and
their amplification was determined by comparing the
amount of infectious particles present in cell lysates at
early times after infection (4 h for Ad-OSM and 1 h for
NDV-OSM), and 48 h later. As shown in Figs. 1b-e, both
human and hamster cell lines were permissive for repli-
cation of the viruses. In agreement with their respective
lytic cycles, Ad-OSM produced more infectious units
(iu)/cell compared with NDV-OSM. The full replicative
potential of Ad-OSM was achieved when cells were in-
cubated with the hypoxia-mimicking agent CoCl2, which
increases the production of hypoxia-inducible factor
(HIF-1α) and stimulates the hypoxia-responsive ele-
ments (HRE) present in the artificial promoter used to
control E1A expression in this virus [32]. To verify that
the incorporation of OSM into the genome of the OVs
did not interfere with replication, we performed a side
by side comparison with replication-competent viruses
expressing the reporter gene eGFP or the suicide gene
thymidine kinase (TK) from HSV-1 (Fig. 1a). NDV-
LaSota-F3aa-EGFP (NDV-GFP) incorporates eGFP be-
tween the P and M genes. Ad-TK9 is identical to Ad-
OSM except for the presence of the TK gene instead of
hOSM. Ad-WT-CMV-GFP (referred to here as Ad-GFP)
is identical to the wild type human Ad5, except for the
incorporation of an expression cassette for eGFP in the
E3 region. Therefore, it presents unrestricted replication.
No significant differences were observed in the amplifi-
cation of viruses containing OSM and GFP or TK in any
of the cell lines (Figs. 1b-e). Next, we studied the oncoly-
tic (cytopathic) effect of these viruses in vitro, and con-
firmed that the incorporation of OSM does not alter
their potency (data not shown). Interestingly, NDV
showed a stronger cytopathic effect in HaP-T1 cells
compared with Ad (Fig. 2b), despite equivalent infectiv-
ity (Fig. 2a) and a lower amplification index (Fig. 1c,e),
reflecting the differences in the lytic cycle of both vi-
ruses. The enhanced oncolytic potency of NDV-OSM
was particularly evident in human PDAC cells, PANC-1
and BxPC-3 (Fig. 2c,d), despite equivalent infectivity
(data not shown). To rule out the possibility that Ad and
NDV could inhibit each other in case of co-infection, we
studied the cytotoxic effect obtained in HaP-T1 cell cul-
tures co-infected with Ad-OSM and NDV-OSM, in
comparison with single NDV-OSM infection. In Fig. 2e
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we represent the change in cytotoxicity of NDV-OSM
caused by the addition of Ad-OSM at each MOI. Our
results indicate that there is virtually no change in the
potency of NDV-OSM at high MOIs, whereas a moder-
ate increase is observed at low-intermediate MOIs. This
result indicates that Ad does not interfere with the onco-
lytic effect of NDV.
Human and Syrian hamster PDAC cells respond to
recombinant or virally encoded hOSM
To investigate the biological activity of hOSM in Syrian
hamsters, HaP-T1 cells were incubated with 20 ng/ml
recombinant hOSM, and phosphorylation of STAT3 was
detected by western blot analysis at different times as an
indicator of downstream signaling. As shown in Fig. 3a,
a rapid activation of STAT3 was detected in these cells.
Furthermore, hOSM treatment caused up regulation of
downstream genes such as IL-15Rα and ICAM1 with
similar intensity in human and Syrian hamster PDAC
cell lines, as shown in Fig. 3b. Next, HaP-T1 cells were
infected with Ad-OSM, NDV-OSM or their reporter
virus counterparts, and conditioned medium was col-
lected 48 h later for quantification of hOSM by ELISA.
As shown in Fig. 3c, the cytokine was detected in cells
infected with both hOSM-expressing viruses. The bio-
logical activity of the virally encoded hOSM was verified
by incubation of the liver-derived human cell line HuH-
7 with these media. As previously reported [17], hOSM
stimulated the phosphorylation of STAT1 in these cells
(Fig. 3d). Of note, no type I IFN activity was detected in
these conditioned media from HaP-T1 cells by bio-assay
(data not shown), and by analysis of IFN-stimulated
genes mRNA expression on hamster cell lines (Additional
file 1: Figure S1). These results indicate that Ad-OSM and
NDV-OSM achieve expression of functional hOSM in in-
fected cells, and neither of these viruses stimulates pro-
duction of type I IFN in vitro in this particular cell line. In
agreement with this observation, HaP-T1 and PANC-1
Fig. 1 Ad-OSM and NDV-OSM replicate in human and hamster PDAC cells. a Schematic representation of the main viruses used in this study. ITR,
adenovirus inverted terminal repeat; ΔE1A 922–947 indicates the nucleotides deleted from the E1A gene; ΔE3 6.7/gp19K indicates the
deletion of these genes in the E3 region; GFP, enhanced green fluorescence protein; TK, thymidine kinase from HSV-1; NP, P, M, F, HN and L are
NDV genes. b-e Quantification of infectious particles produced at the indicated times in PANC-1 and HaP-T1 cells infected with the different
viruses (representative results of at least 2 experiments performed in triplicate). Black columns correspond to cells treated with the hypoxia-mimetic
drug CoCl2. * p <0.05, ** p <0.01
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cells directly infected with Ad-OSM or NDV-OSM showed
specific stimulation of OSM downstream genes such as IL-
15Rα and ICAM1 (Fig. 3e), but not others associated with
the combination of OSM and IFNα such as Tap1 or β2-
microglobulin (data not shown). Together, these in vitro re-
sults indicate that infection of PDAC cells with Ad-OSM
or NDV-OSM viruses achieves secretion of functional
hOSM, which is active in both human and hamster cells
and stimulates the expression of immunostimulatory genes.
Toxicity and antitumor effect of Ad-OSM and NDV-OSM in
vivo
Orthotopic pancreatic cancer tumors were established in
Syrian hamsters by inoculation of HaP-T1 cells. This
model recapitulates the key genetic and histopathological
characteristics of human PDAC [31, 34], forming highly
aggressive and infiltrative adenocarcinomas as shown in
Fig. 4a. Once tumor masses were evident by ultrasound or
physical examination (average volume 200 mm3), ham-
sters were divided into groups that received different
doses of either Ad-OSM or NDV-OSM, or were left un-
treated (injection of saline solution). A schematic repre-
sentation of the experimental setting is shown in the right
panel of Fig. 4a. Viruses were administered by direct intra-
tumoral injection (day 0), and the same dose was repeated
at day 3. This schedule was chosen based on previous ex-
perience showing that the transgene expression of re-
peated Ad administrations is blocked by neutralizing
antibodies (NAb) as early as 7 days after the first virus in-
oculation (Additional file 1: Figure S2 and Additional file
Fig. 2 NDV-OSM shows stronger oncolytic effect than Ad-OSM on PDAC cells in vitro. a Percentage of transduced (GFP+) HaP-T1 cells 24 h after
infection with Ad-GFP and NDV-GFP at the indicated MOIs. b-d cells were infected at different MOIs (X-axis, logarithmic scale) and the percentage of
viable cells remaining in the monolayer was quantified 5 days later by crystal violet staining (representative results of at least 2 experiments with 4
samples per point). Uninfected cells were used as a reference (100 % survival). e HaP-T1 cells were co-infected with equal MOIs of Ad-OSM
and NDV-OSM, or infected with NDV-OSM only. The change in cytotoxic effect (enhancement or inhibition) is represented as a positive or
negative percentage, respectively, considering 0 the value obtained by single NDV-OSM infection at each MOI
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2). Quantification of hOSM in serum of animals revealed
important differences between viruses. Infection of Ad-
OSM was very efficient inducing hOSM secretion, causing
a transient, dose-dependent systemic elevation of the cyto-
kine (Fig. 4b). The efficacy of the second virus administra-
tion was demonstrated in a separate group of hamsters
that received 2.5 × 108 iu Ad-OSM and were monitored
for serum hOSM at days 1, 3 and 4 (Fig. 4c). Active virus
replication was detected in these samples (Additional file
1: Figure S4). In the highest dose group (1 × 109 iu/ham-
ster), serum hOSM concentrations reached a peak of
3000 pg/ml at day 1, and caused severe toxicity with
>50 % mortality during the first week after treatment.
Equal doses of Ad-GFP or other replication-competent
Ad carrying reporter genes were well tolerated (data not
shown). Toxicity was not accompanied by elevation of
Fig. 3 Human OSM is biologically active on PANC-1 and HaP-T1 cell lines. a Western blot analysis of STAT3 activation in HaP-T1 cells treated with
20 ng/ml of recombinant hOSM at the indicated times. b mRNA levels of IL-15Rα and ICAM1, determined by qRT-PCR in HaP-T1 and PANC-1 cell
lines treated with 20 ng/ml of recombinant hOSM at the indicated times. c Concentration of hOSM in the conditioned medium of HaP-T1 cells
infected for 24 h with the indicated MOIs of Ad-OSM and NDV-OSM, determined by ELISA. d Western blot analysis of STAT1 activation in HuH-7 cells
treated with conditioned medium from HaP-T1 cells infected or not with Ad-OSM, NDV-OSM or their respective GFP-expressing controls. e mRNA
levels of IL-15Rα and ICAM1, determined by qRT-PCR, in HaP-T1 and PANC-1 cell lines treated for 24 h with the same conditioned media (representative
results of at least 2 experiments performed in triplicate). ** p <0.01
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Fig. 4 (See legend on next page.)
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transaminases in serum nor hematological abnormalities
(data not shown), suggesting lung inflammation as the
most likely cause of death [35]. In fact, histological exam-
ination of these organs revealed severe edema, inflamma-
tory infiltrate and extracellular matrix accumulation
(Additional file 1: Figure S3). In contrast, hamsters treated
with 1 × 109 or 5 × 109 iu NDV-OSM showed no detect-
able hOSM in serum at any time. Only moderate concen-
trations of the cytokine (below 200 pg/ml) were observed
when the virus was used at 1 × 1010 iu/hamster, but no
treatment-related deaths occurred in this group. On the
other hand, NDV-OSM was able to stimulate endogenous
production of type I IFN in the animals starting at 1 × 109
iu, whereas Ad caused no elevation of serum type I IFN
even at the highest dose (Fig. 4b, right panel). All animals
were sacrificed one month after initiation of treatment for
direct assessment of tumor progression (Fig. 4d). The
average tumor volumes were reduced in all treated groups
as compared with untreated animals, but differences did
not reach statistical significance. In the case of Ad-OSM,
the intermediate dose (2.5 × 108 iu) achieved tumor eradi-
cation in close to 50 % of the animals, but intensification
of the treatment to improve the percentage of complete
responses was not possible due to the toxicity associated
with the release of hOSM into the circulation. In contrast,
higher dose escalation of NDV-OSM was possible due to
its lower toxicity, but no improvement in the therapeutic
effect was observed by increasing the dose beyond 1 × 109
iu/hamster. Additional hamsters treated with 2.5 × 108 iu
Ad-OSM or 1 × 109 iu NDV-OSM were sacrificed 48 h
after the first virus administration for histological analysis
of tumor samples. The most significant finding was a
marked increase in necrotic areas observed in tumors
treated with NDV-OSM, accompanied by acute inflamma-
tory infiltration (Fig. 4e). This is consistent with the strong
oncolytic effect observed in PDAC cells infected with this
virus in vitro.
Sequential combination of Ad-OSM and NDV-OSM is safe
and improves the antitumor effect of these agents
The results obtained in the first in vivo experiments
(Fig. 4) with Ad-OSM and NDV-OSM indicated that
safety and efficacy of this approach should be improved.
To this end, we tested a new protocol in which low
doses of the viruses (1 × 108 iu) were combined sequen-
tially in two cycles one week apart, as depicted in Fig. 5a.
(See figure on previous page.)
Fig. 4 Ad-OSM and NDV-OSM show limited antitumor effect as monotherapy. Tumors were established by intrapancreatic inoculation of HaP-T1
cells. a Left panel shows the histopathological examination of a representative tumor (Hematoxylin/Eosin staining, magnification x400). Note the
infiltration of normal pancreas and engulfment of secretory acini (white arrows). Right panel shows a schematic representation of the experimental
setting. Treatments started 2 weeks after cell implantation (referred to as day 0) by intratumoral (i.t.) injection of Ad-OSM or NDV-OSM (n = 6-12).
Control animals received the same volume of saline solution (n = 12-16). A second dose of each virus or saline was administered at day 3. All hamsters
were sacrificed one month after the initiation of treatment. b Concentration of hOSM and type I IFN in the serum of hamsters 24 h after treatment with
the indicated viruses, determined by ELISA and bioassay, respectively. Viral doses correspond to i.u. (x108). c Apart from the efficacy study, an independent
group of tumor-bearing hamsters (n= 5) received Ad-OSM at 2.5 × 108 i.u. at days 1 and 3 (arrows), and serum hOSM concentration was quantified right
before and 24 h after each virus administration. d Individual tumor volumes and group averages determined by necropsy one month after initiation of
treatments in the efficacy study. n.d., not determined due to early death of animals. e Additional groups of hamsters (n = 5) received
Ad-OSM (2.5 × 108 i.u/hamster), NDV-OSM (1 × 109 iu/hamster) or saline (control), and were sacrificed 48 h after treatment for histopathological
examination of tumors. Microphotographs show Hematoxylin/Eosin staining, magnification X100). The percentage of necrotic area in each
group (n = 5) is represented in the right panel. * p < 0.05, ** p < 0.01
Fig. 5 Sequential administration of low dose Ad-OSM and NDV-OSM is safe and inhibits progression of PDA tumors in hamsters. a Schematic
representation of the experimental setting. Tumor-bearing hamsters were divided into 4 groups that received the following treatments: local
administration of Ad-OSM at days 0 and 3, followed by two administrations of NDV-OSM at days 10 and 13 (Ad/NDV-OSM group, n = 12); the
same viruses in the reverse order (NDV/Ad-OSM group, n = 12); Ad-GFP followed by NDV-GFP (Ad/NDV-GFP group, n = 5); or local injections of
saline solution at days 0, 3, 10 and 13 (Control group, n = 19). All viral doses were 1 × 108 iu/hamster. b Individual tumor volumes and group averages
determined by necropsy one month after initiation of treatments. * p < 0.05
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A combination of viruses expressing GFP was included
to assess the role of direct viral oncolysis on the efficacy
of treatment. As expected, no elevations of hOSM or
IFNα were detected in the serum of treated hamsters in
any of the groups (data not shown). Importantly, a sig-
nificant antitumor effect was observed only in hamsters
treated with the combinations of Ad-OSM and NDV-
OSM, irrespective of the order of administration
(Fig. 5b). This result suggests that the antitumor effect
requires local OSM expression mediated by the OVs,
which is effective at levels below the threshold required
for appreciable secretion into the bloodstream. Since tol-
erance to this treatment was good and there was room
for improving efficacy, we performed new experiments
in which optimal intratumoral doses of Ad-OSM and
NDV-OSM (2.5 × 108 and 1 × 109 iu, respectively) were
used sequentially. Instead of tumor measurement after
sacrifice, we studied long-term survival of animals. To
assess the importance of combining different viruses,
additional groups were included in which each cycle of
treatment consisted of the same virus (Fig. 6a). This ad-
ministration protocol allowed us to study the impact of
humoral immunity on the efficacy of our virotherapy ap-
proach. When we examined the serum of animals in the
middle of the second cycle of treatment (day 11), we
confirmed the presence of NAbs at high titers against
the virus used in the first cycle (Fig. 6b), suggesting that
the only protocol that preserves the efficacy of the sec-
ond round of infection is sequential administration. In
agreement with this observation, this was the only group
that showed a reduction in tumor progression (Fig. 6c)
and a significant increase in survival compared with un-
treated animals in this aggressive tumor model (Fig. 6d).
Finally, we studied if this protocol was able to stimulate
the immune response against cancer cells. To this end,
splenocytes obtained from long-term survivors were ex-
panded in the presence of irradiated HaP-T1 cells and
then exposed to the same cells. We observed an increase
in IFNγ and FasL expression, compared with splenocytes
obtained from tumor-bearing hamsters that received no
treatment (control) or healthy (naïve) hamsters (Fig. 6e).
This type of response has been previously associated
with efficient antitumor immune responses in Syrian
hamsters treated with OAVs expressing other cytokines
[29]. To further explore the involvement of the immune
system in the therapeutic effect of the treatment, we car-
ried out an additional experiment in which one group of
treated animals were immune suppressed by cyclophos-
phamide treatment, as previously described [36]. Al-
though this drug enhances virus replication and spread
in hamsters, the net balance was a negative impact on
the antitumor effect. All animals treated with cyclophos-
phamide showed tumor progression, in contrast with 3
out of 7 hamsters with complete tumor remission and
70 % long-term survivors in the immune competent
group (Fig. 7a). Finally, these animals received a sub-
cutaneous re-challenge with HaP-T1 cells to determine
the presence of a protective immune response. Only a
slight retardation in tumor appearance was observed in
2 hamsters that had rejected their primary tumor
(Fig. 7b). This result suggests that immune competence
is required for the therapeutic effect of OVs expressing
hOSM, although a robust immunological protection was
not detected.
Discussion
Progress in the field of virotherapy has led to a situation
in which a wide repertoire of OVs is available for clinical
testing, and the incorporation of immunostimulatory
transgenes is showing the most promising results in pa-
tients [3–6, 37, 38]. New possibilities are now feasible,
including the combination of OVs and the evaluation of
different cytokines as therapeutic genes [39–42]. In this
scenario the safety and efficacy of treatments not only
depends on the potency and selectivity of virus replica-
tion, but also on other parameters such as the type of
tumor and its immune properties, the expression of the
transgene and the host antiviral responses. Our orthoto-
pic PDAC model in Syrian hamsters has enabled us to
characterize the properties of Ad and NDV OVs armed
with hOSM, alone or in combination. One of the most
relevant differences observed between both agents was
their capacity to secrete hOSM into the circulation upon
intratumoral administration. NDV-OSM required higher
doses to cause elevations of this cytokine in the serum
of animals as compared with Ad. This behavior was diffi-
cult to predict in vitro by analyzing the presence of
hOSM in the conditioned medium of infected cells,
probably because secreted proteins accumulate in the
isolated compartment of the culture dish. We found no
significant differences between either virus in these as-
says, but the situation in vivo revealed important differ-
ences. The stronger and faster cytolytic effect of NDV
may determine that tumor cells initially infected with
this virus can only express the transgene for a short
period of time compared with Ad. Since virus amplifica-
tion is rapidly controlled by the innate immune system
[22, 43] and the secreted hOSM is constantly diluted in
the bloodstream, the net balance is a low cytokine con-
centration in the circulation. The combination of a
strong cytolytic effect and low capacity to secrete the
therapeutic protein into the bloodstream is desirable
when the transgene is potentially toxic, as is the case of
OSM. In contrast, cells infected with Ad retain their via-
bility for a prolonged period of time (48 to 72 h) and
sustain a robust amplification of viral genomes, resulting
in a very efficient expression of transgenes. As a conse-
quence, Ad-OSM caused severe toxicity at relatively low
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Fig. 6 (See legend on next page.)
Nistal-Villan et al. Molecular Cancer  (2015) 14:210 Page 10 of 16
viral doses (1 × 109 iu/hamster), insufficient to exert a
relevant cytolytic effect in the tumor mass. A similar ob-
servation has been recently reported with an oncolytic
Ad expressing IL-12 [30]. Although we observed a clear
dose-dependent production of hOSM in hamsters, es-
tablishment of the maximal tolerated dose in fully per-
missive hosts such as humans may be difficult because
expression of the transgene will largely depend on the
replication of viral genomes in tumors. Whereas the
biological effect of hOSM may account for most of the
antitumor effect observed with Ad-OSM, in the case of
NDV-OSM the contribution of direct viral oncolysis
may have certain relevance. In any case local expression
of hOSM is crucial also for this virus, because no sig-
nificant antitumor effect was observed when the NDV-
GFP virus was used in this model, alone (data not
shown) or in combination with Ad-GFP. Another pecu-
liarity of NDV-OSM was its strong capacity to stimu-
late the endogenous production of type I IFN. Again,
this was observed only in vivo, indicating that the
source of type I IFN is the hamster immune system and
not the tumor parenchyma. As type I IFN is essential in
promoting CD8 mediated immune responses the con-
comitant expression of OSM and type I IFN may lead
(See figure on previous page.)
Fig. 6 Sequential administration of Ad-OSM and NDV-OSM improves survival of tumor-bearing hamsters and stimulates immune response against
cancer cells. a Schematic representation of the experimental setting. Tumor-bearing hamsters were divided into 4 groups (n = 6) that received the
following treatments: Four local administrations of Ad-OSM (2.5 × 108 iu/hamster) or NDV-OSM (1 × 109 iu/hamster) at days 0, 3, 10 and 13
(Ad/Ad-OSM and NDV/NDV-OSM groups, respectively); or Ad-OSM (2.5 × 108 iu/hamster) at days 0 and 3, followed by NDV-OSM (1 × 109 iu/hamster) at
days 10 and 13 (Ad/NDV-OSM group). b NAbs against Ad (top panel) or NDV (lower panel) were quantified in serum of hamsters at days
11 and 24. Ad/Ad-OSM, NDV/NDV-OSM and Ad/NDV-OSM groups are represented as black, grey and striped bars, respectively. c Progression of tumors
in the different groups. Each line represents an individual hamster. d Percentage of surviving animals in each group. e Long-term survivors were
sacrificed at day 70 and spleens were collected. Splenocytes were expanded for 5 days in the presence of irradiated HaP-T1 cells and IL-2, and
then exposed for 8 h with fresh HaP-T1 cells. Expression of IFNγ and FasL was determined by qRT-PCR and compared with splenocytes from a
group of untreated tumor-bearing hamsters sacrificed 40 days after cell implantation (saline), or healthy, naïve hamsters. * p < 0.05, ** p < 0.01
1
Fig. 7 Immunosuppression abrogates the antitumor effect of OVs expressing OSM. The experimental setting is as described in Fig. 6. Treatment
groups (n = 6/7) included control (saline solution injection); cyclophosphamide (CP); sequential administration of Ad-OSM and NDV-OSM (Ad/NDV-OSM)
and the same treatment in combination with cyclophosphamide (Ad/NDV-OSM + CP). a Progression of tumors in the different groups. Each
line represents an individual hamster. The numbers indicate the number of animals with complete response/total. In the Ad/NDV-OSM group
the individuals with progressive disease, partial response and complete response are indicated by red, blue and green lines, respectively.
b Long-term survivors from the Ad/NDV-OSM were subjected to a subcutaneous re-challenge with HaP-T1 cells. The graphs indicate the progression
of tumors in each animal. A group of untreated hamsters bearing pancreatic tumors were used as a control
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to synergistic immunostimulatory effects. Detailed ana-
lysis of the mechanism of action requires generation of
new tools to study the immune system in Syrian ham-
sters, but our data demonstrate that local expression of
OSM mediated by repeated administration of antigeni-
cally unrelated OV is needed to induce antitumor ef-
fects in a difficult-to treat- neoplasm. The therapeutic
effect is associated with the induction of cellular re-
sponses against cancer cells and requires a competent
immune system, although efficient protection from
tumor recurrence at distant sites was not demonstrated
in re-challenge experiments. This may reflect the im-
portance of tumor microenvironment in the immune
evasion of PDAC [44].
Conclusions
Our study provides evidence that OSM promotes the ex-
pression of immunostimulatory genes in PDAC cells. In-
corporation of this cytokine into oncolytic Ad and NDV
viruses does not impair their replicative and cytolytic
potential. Syrian hamsters carrying orthotopic PDAC tu-
mors are sensitive to hOSM and permissive for replica-
tion of both OVs. Local expression of hOSM is required
for the antitumor effect of Ad-OSM and NDV-OSM,
but serum concentrations above 3000 pg/ml cause se-
vere toxicity. Sequential administration of Ad-OSM and
NDV-OSM avoids the interference of neutralizing anti-
bodies, allowing two cycles of hOSM expression in tu-
mors. This protocol achieves a significant antitumor
effect and prolongs the survival of animals using safe
doses of viruses. We believe this principle can increase
the safety and efficacy of other immunovirotherapy
approaches.
Methods
Cells
Syrian hamster cells HaP-T1 (DSMZ ACC 222) and
H2T (courtesy of Dr. CM Townsend, University of
Texas Medical Branch, TX, USA), and human cell lines
HuH-7 (JCRB Genebank, Japan), Hep2 (ATCC CCL-23),
A549 (ATCC CCL-185), BxPC-3 (ATCC CRL-1687) and
PANC-1 (ATCC CRL-1469), were maintained in Dulbec-
co’s modified Eagle’s medium (Invitrogen) supplemented
with 10 % fetal calf serum, 100 μg/ml streptomycin and
100 units/ml penicillin. For STAT3 activation analysis by
western blot, 1.5 × 105 HaP-T1 cells were seeded in a
6-well plate and 24 h later cells were treated with
20 ng/ml of hOSM (R&D) for 20 and 35 min. For
quantification of IL-15Rα and ICAM1 mRNA levels,
1.2 × 104 HaP-T1 or PANC-1 cells were seeded in a
96-well plate and 24 h later were treated with 20 ng/ml of
hOSM for 24 and 48 h.
Plasmid constructions
The coding sequence of hOSM was obtained as previ-
ously described [45]. The genome of Ad-OSM was based
on the previously described virus Ad-IL12G [32], in
which the single chain IL-12 coding sequence was re-
placed by hOSM, using standard molecular biology tech-
niques. The same procedure was used to incorporate the
HSV-1 thymidine kinase gene in the genome of the Ad-
TK9 virus. The following specific primers:
S_SacII_NDV_hOSM: CCGCGGTTAGAAAAAATAC
GGGTAGAACCGCCACCatgGGGGTACTGCTCACA
CAG and A_SacII_NDV_hOSM: CCGCGGATCATCT
CCGGCTCCGGTTCGGGC were used to amplify the
transgene in order to insert the hOSM sequence into
the NDV genome between the P and M genes. The
same strategy was used to clone GFP into the NDV
genome using the following primers to amplify GFP by
PCR as described for hOSM: S_SacII_NDV_GFP:CC
GCGGTTAGAAAAAATACGGGTAGAACCGCCACC
ATGGTGAGCAAGGGCGAGG and A_SacII_NDV_GFP:
CCGCGGATTACTTGTACAGCTCGTCC.
NDV virus rescue
The NDV LaSota mutant viruses engineered to express
eGFP or hOSM were generated as previously described
[46] with some modifications. A549 and Hep2 cells were
infected in a 6-well plate with MVA-T7 and one hour
later, virus was removed and cells were transfected with
viral genomes as described before [46]. Eighteen hours
later, both cells and supernatants were mixed and
injected into 8-day old chicken embryonated eggs. After
three days of incubation, virus rescue was detected by
the hemagglutination assay and sequenced by RT-PCR
to verify insert fidelity. Immunofluorescence in Hep2
cells was performed to titrate rescued virus. To prepare
virus stocks, 8-days old chicken embryonated eggs were
used to grow original rescued virus by injecting approxi-
mately 500 iu per egg. Two days later, egg allantoic fluid
was collected and virus stocks were prepared and frozen
at −80 °C.
NDV virus titration
NDV stocks were titrated by indirect immunofluores-
cence in Hep2 cells using polyclonal anti-NDV sera ob-
tained from rabbits immunized with the virus followed
by the use of a secondary goat anti-rabbit IgG (H + L)
secondary antibody, Alexa Fluor® 488 conjugated (Life
Technologies). Virus titer was determined by calculating
TCID50 using the Reed-Muench method [47].
Adenovirus production and quantification
All adenoviral vectors were derived from human sero-
type 5. Plasmids containing viral genomes were linear-
ized by PacI digestion (New England Biolabs), ethanol-
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precipitated and transfected in HEK-293 cells by Lipo-
fectamine 2000 (Invitrogen). Cells were collected when
the cytopathic effect was evident, and viral particles
were obtained by 3 cycles of freeze/thaw. Viral clones
were isolated by serial dilution in HEK-293 cells before
amplification in the same type of cells.
Virus was purified by ultracentrifugation in a CsCl
gradient. Infectious units were quantified using the
Adeno-X rapid titer kit (Clontech). The Ad-WTLuc
virus [29] is based on wild type adenovirus type 5 with
insertion of the luciferase gene into the E3 region (sub-
stitution of the E3-6.7 K/gp19K genes). The same loca-
tion was used to incorporate an EGFP expression
cassette in the Ad-WT-CMV-GFP virus [30].
Animals and treatment procedures
Orthotopic pancreatic cancer tumors were established in
Syrian (Golden) hamsters (Mesocricetus Auratus; HSD
HAN: AURA, 5 weeks of age, Harlan) using a method
modified from Abraham et al. [34]. HaP-T1 cells (2 × 106
cells resuspended in 50 μl saline) were injected into the
splenic lobe of the pancreas through lateral laparotomy
under inhaled anesthesia. This anatomical location facili-
tates repeated intratumor injection of treatments with-
out the need of further laparotomies, resulting in a
refinement of the animal procedure. When tumors
reached at least 200 mm3 (typically 2 weeks after cell
implantation), local administration of OAVs were per-
formed by percutaneous injection in a total volume of
50 μl saline solution. Control animals received the same
volume of vehicle. Average pre-treatment tumor volume
was equivalent in all experimental groups. Tumor
volumes were calculated at necropsy using the formula
V = (Dxd2)/2, where D and d are the major and minor
diameters, respectively. Re-challenge experiments were
carried out by subcutaneous inoculation of 1 × 106 HaP-
T1 cells. Cyclophosphamide was administered intraperi-
toenally. The schedule consisted of an initial dose of
140 mg/Kg one week before the first virus administra-
tion, and then 100 mg/Kg twice weekly for 2 weeks [36].
All procedures were carried out following protocols ap-
proved by the local ethics committee in accordance with
recommendations for proper care and use of laboratory
animals.
Histological analysis and quantification of tumor necrosis
Tumor sections were fixed, paraffin-embedded and
stained with Hematoxylin and Eosin following standard
procedures. Samples were randomized (Research ran-
domizer, https://www.randomizer.org/) and the percent-
age of necrotic area in tumors was quantified using
Image J software in a blinded fashion.
Western blot assays
Western blot analyses were performed as previously
described [17].
Analysis of gene expression
Total RNA from cells was extracted using the automated
MagMax Express 96 system (Applied Biosystems) using
the Magmax-96 total RNA isolation kit (Life Technolo-
gies). Reverse transcription (RT) was performed as previ-
ously reported [48]. Real-time polymerase chain
reactions (PCRs) were performed with iQ SYBR Green
supermix (Bio-Rad) in a CFX96 system from Bio-Rad,
using specific primers for each gene (Table 1). The
amount of each transcript was expressed by the formula:
2ct(β-actin or CD3)−ct(gene), ct being the point at which the
fluorescence rises appreciably above the background
levels.
Table 1 Primers used in this study
Gene Sense primer (5´-3´) Antisense primer (5´-3´)
Hamster IL-15Rα ACACAAATACTGCCCACTGG TCCAAGGTCATTGTTGCTGC
Hamster ICAM1 CATGGAGCCAGTTTCTCATG ATCACTTTCTGCATGGTGCC
Human IL-15Rα GGAACCACAGAGATAAGCAG CCTTGACTTGAGGTAGCATG
Human ICAM1 CCGAGCTCAAGTGTCTAAAG CCTTTTTGGGCCTGTTGTAG
Hamster IFNγ GGCCATCCAGAGGAGCATAG CCATGCTGCTGTTGAAGAAGTTAG
Hamster FasL AAGAAGAGGAAGGACCACAG TTTTCAGAGGGTTGACTCGG
Hamster CD3 CGGCGAAAGTATGGTTTACC TGCTCGTTCTTCAACAGAGC
Hamster Tap1 CGTTCTCAGTTATGTAGCAG CCCGTGAAGAAAGGAATGGC
Hamster B2M ATGCCATCCAGCGTCCCC ATCGGTCGCAGTGGGTGTAA
Hamster OAS CTCATCCGCCTGGTCAAGC GGGTCCAGGATCACAGGC
Hamster GBP1 TGGCATCAGAGATCCACATG ACACACCACATCCAGATTCC
Hamster actin GTCGTACCACTGGCATTGTG GTCACGCACAATTTCCCTCT
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Quantification of human OSM protein levels
Concentration of hOSM in cell supernatants was deter-
mined 24 h after infection with Ad-OSM or NDV-OSM
by enzyme-linked immunosorbent assay (ELISA, R&D)
according to the manufacturer’s instructions. The same
method was used to measure hOSM in the serum of
hamsters.
Analysis of immune response against HaP-T1 cells
Spleens were removed from the euthanized animals, and
splenocytes were isolated by passing the spleens through
70 μm nylon mesh filters. Splenocytes (3 × 106 cells/well)
were co-cultured with 1.5 × 105 irradiated HaP-T1 cells
in 24-well plates for 8 days. On day 3, 50 units/ml of IL-
2 were added to co-cultures. After 8 days, splenocytes
were collected and seeded (1 × 105 cells/well) together
with 1 × 104 fresh HaP-T1 cells in 96-well plates. After
8 h of co-culture, the cells were collected in lysis/bind-
ing solution (Life Technologies) for total RNA extraction
and subsequent IFNγ and Fas Ligand mRNA expression
study. The amount of each transcript was expressed by
the formula: 2ct(CD3)−ct(gene).
Type I IFN bioassay
The antiviral activity of hamster type I IFN present in
serum or cell supernatants was analyzed by measuring
its ability to protect hamster H2T cells against the cyto-
pathic effect of encephalomyocarditis virus (EMCV).
The assay was performed in a 96-well microtiter plate.
First, 2 × 104 H2T cells per well were seeded in 150 μl of
medium containing serial dilutions of serum or condi-
tioned media from cells infected with Ad or NDV. The
viruses were previously UV-inactivated. After incubation
for 24 h, cells were infected with EMCV (5 × 106 pfu per
well), and 24 h later, the cytopathic effect was measured
by staining with crystal violet dye solution (0.5 % in 1/
4 v/v methanol/water). The optical density was read at
595 nm. At the same time, serial dilutions of human
IFNα (PBL Biomedical Laboratories) were tested to ob-
tain a standard curve. Results are expressed as units/ml
and were calculated interpolating the optical density of
each sample in the standard curve.
Quantification of neutralizing antibodies
Anti-adenovirus type 5 neutralizing antibodies were
determined using a modified luciferase-based virus
neutralization assay, as previously described [49]. In the
case of NDV, the reporter virus NDV-GFP was serially
diluted in a 1:2 series. A virus dilution corresponding to
the last dose presenting close to 100 % GFP signal in
Hep2 cells was later used for incubation at 25 °C for 2 h
with hamster sera. Ab neutralizing titers were obtained
in quadruplicate using the Reed-Muench method to cal-
culate the inhibitory ED50 also in Hep2 cells.
Statistical analysis
The Mann Whitney test was applied for statistical compari-
son of two groups. Comparisons of more than two groups
were performed by ANOVA with Bonferroni correction.
Survival differences were analyzed by the Log-Rank (Man-
tel-Cox) test using the GraphPad Prism program (Graph-
Pad Software). Unless otherwise stated, triplicate samples
were used for in vitro experiments. For animal studies, a
sample size estimate was obtained from http://www.bio-
math.info/power/index.htm. The number of animals per
group is indicated in the scatter plot graphs. Unless other-
wise stated, all experiments were repeated at least twice.
Additional files
Additional file 1: Additional Figure S1 Measurement of type I IFN in
conditioned media from HaP-T1 cells infected with of Ad or NDV.
H2T cells were exposed for 8 h to conditioned media from HaP-T1 cells
infected during 24 h with the indicated viruses. mRNA levels of the type I
IFN stimulated genes OAS (a) and GBP1 (b) were determined by qRT-PCR.
H2T cells treated with conditioned media from uninfected cells (control)
or cells treated with 500 units/ml recombinant human IFNα are included
as negative and positive controls, respectively (representative results of at
least 2 experiments performed in triplicate). *** p < 0.001. Additional
Figure S2 Rapid onset of NAbs reduces the efficacy of Ad redosing.
Hamsters bearing orthotopic pancreatic cancer tumors received a local
administration of Ad-WT-Luc (1 × 109 iu/hamster) at day 0 and were then
separated into two groups (n = 4). One of them received a second
administration of the same dose of virus at day 3 (a) and the other one
received it at day 7 (b). Expression of luciferase was quantified by in vivo
bioluminescence imaging at the indicated times. The graphs show total
light emission (in photons/s) measured from the tumor area. (c)
Representative image of a hamster expressing luciferase at day 1,
showing the region of interest for quantification. Note the predominant
light emission in the anatomical region corresponding to the injected
pancreatic tumor (left panel, ventral view; right panel, lateral view). In
the artificial color code, red and blue represent maximal and minimal
light emissions, respectively. Additional Figure S3 Elevation of OSM
in serum causes severe lung inflammation in Syrian hamsters.
Animals treated with 1 × 109 iu Ad-OSM show signs of toxicity and most of
them die or require euthanasia during the first week after virus administra-
tion. The microphotographs show histopathological examination of lungs
from representative animals from the untreated (control) and Ad-OSM-
treated groups (Hematoxylin-Eosin, x200). Note the presence of edema,
inflammatory infiltrate and deposition of extracellular matrix. Additional
Figure S4 Ad-OSM replicates in PDAC tumors in vivo. Hamsters bearing
orthotopic pancreatic cancer tumors received a local administration of
Ad-OSM at 2.5 × 108 iu/hamster (n = 5) or a first-generation adenoviral
vector encoding luciferase (AdCMVLuc) at 2 × 109 iu. Hamsters were
sacrificed 4 days later for tumor collection. (a) Quantification of infectious
units in tumor
lysates (expressed as iu/mg tissue). (b) Detection of hexon expression in
tumor cells by immunohistochemistry. A cluster of positive cells is marked
by a black arrow (200x magnification). (PDF 1298 kb)
Additional file 2: Additional methods. In vivo bioluminescence
detection. Anesthetized hamsters received an intraperitoneal injection of
9 mg D-Luciferin Firefly (Sigma) dissolved in 300 μl PBS. Five minutes later
they were placed in a dark chamber connected to an in vivo luminescent
detection system (IVIS, Xenogen). Photon emission was quantified using
the Living Image Software (Xenogen). (DOC 22 kb)
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